Stockscreener 앱 받기
21.04
2.14%
-0.46
시간 외 거래:
21.19
0.15
+0.71%
전일 마감가:
$21.50
열려 있는:
$21.04
하루 거래량:
482.22K
Relative Volume:
2.00
시가총액:
$2.73B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-2.00%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$20.75
$21.77
1주일 범위
$20.75
$23.62
52주 변동 폭
$20.75
$28.23
Kailera Therapeutics Inc Stock (KLRA) Company Profile
Compare KLRA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KLRA
Kailera Therapeutics Inc
|
21.04 | 2.79B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kailera Therapeutics Inc 주식(KLRA)의 최신 뉴스
How AI is Transforming Health Literacy and Engagement - William Blair
RTW Bio NAV Rises 7.0% In April As Biotech IPO And M&A Activity Accelerates - DirectorsTalk Interviews
Evercore Initiates Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo
TD Cowen Initiates Kailera Therapeutics(KLRA.US) With Buy Rating, Announces Target Price $57 - Moomoo
Kailera Therapeutics, Inc. (KLRA) Total Expenses (TTM) - Zacks Investment Research
What's Going On With Kailera Therapeutics Stock Wednesday?Kailera Therapeutics (NASDAQ:KLRA) - Benzinga
Kailera Therapeutics, Inc. (KLRA) Profit Margin (Quarterly) - Zacks Investment Research
Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions - ChartMill
Kailera Therapeutics, Inc. (KLRA) Dividend Yield (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Market Cap - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Revenue (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Book Value (Per Share) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Net Income (Quarterly) - Zacks Investment Research
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
Kailera's record IPO headlines strong April for biopharma financings - BioWorld News
A Quick Look at Today's Ratings for Kailera Therapeutics(KLRA.US), With a Forecast Between $30 to $48 - Moomoo
Kailera Therapeutics (KLRA) Stock Forecast and Price Target 2026 $KLRA - MarketBeat
Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge - BioSpace
JPMorgan Initiates Kailera Therapeutics at Overweight With $30 Price Target - marketscreener.com
Evercore ISI Kailera Therapeutics Initiates at Outperform - Moomoo
Investment bank Leerink Partners announces the initiation of research coverage on biopharmaceutical company Kailera Therapeutics. - Bitget
TD Cowen initiates Kailera stock with buy on weight loss drug potential - Investing.com Canada
Top Hyperliquid Strategies (PURR) Competitors 2026 - MarketBeat
William Blair initiates Kailera stock with Outperform rating By Investing.com - Investing.com Canada
JPMorgan initiates Kailera stock at Overweight on obesity pipeline By Investing.com - Investing.com Canada
This Southwest Gas Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
Kailera Therapeutics, Inc. (KLRA) Revenue (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Dividend (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Free Cash Flow (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Total Long Term Debt (Quarterly) - Zacks Investment Research
Odyssey raises $304 million in upsized Nasdaq debut - The Pharma Letter
Kailera Therapeutics, Inc. (KLRA) Price To Free Cash Flow - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Gross Profit (TTM) - Zacks Investment Research
KLRA: Kailera Therapeutics, Inc.12 Month EPS - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Earnings Yield (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Return On Equity (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Revenue (Quarterly) Yoy Growth - Zacks Investment Research
KLRA : Kailera Therapeutics, Inc. Key Company Details - Zacks Investment Research
IPO Tracker 2026: Odyssey launches upsized $279M IPO, Seaport docks on Nasdaq - BioSpace
Kailera Therapeutics, Inc. (KLRA) Debt Equity Ratio (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Cash From Operations (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Book Value - Zacks Investment Research
Biotech firm Odyssey hits nearly $900 million valuation as shares rise in Nasdaq debut - WNWN-FM
Kailera Therapeutics, Inc. Stock Data and SignalsKLRA - StockInvest.us
Kailera Therapeutics, Inc. (KLRA) Total Liabilities - Zacks Investment Research
Number of shareholders of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics, Inc. (KLRA) Cash From Financing (Quarterly) - Zacks Investment Research
Biotech firm Odyssey raises $279 million in upsized US IPO - 102.7 WBOW
Kailera Therapeutics, Inc. (KLRA) Price To Cash Flow - Zacks Investment Research
Kailera Therapeutics (KLRA) Stock Analysis Report | Financials & Insights - Benzinga
Kailera Therapeutics Inc (KLRA) 재무 분석
Kailera Therapeutics Inc (KLRA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Kailera Therapeutics Inc 주식 (KLRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
| Koppel Adam | Director |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Bain Capital Life Sciences Inv | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Kaplan Andrew T. | Director |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
0.71%
자본화:
|
볼륨(24시간):